Hepatitis C Virus NS3, Subtype 5, aa1192-1459, Recombinant (HCV)

E.coli derived recombinant from HCV subtype 5. The protein contains the full-length HCV NS3 immunodominant region.\n\nSpecificity: \nImmunoreactive with sera of HCV-infected individuals, including sera with antibodies to NS3 secondary domains.\n\nApplications: \nAntigen in ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems.\n\nStorage: \nProtein is shipped at ambient temperature. Upon arrival, Store at -200C.\n\nStability: \nFive years frozen. One month in solution at room temperature.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

H1920-23T

Size

100ug

Form

Supplied as a liquid in 25mM Tris-HCl, 1mM EDTA, 1.5M urea and 50% glycerol.

Purity

(same/more than) 95% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication.\n\nJ Med Chem 2006 May 4;49(9):2750-7\n\n2. Construction of eukaryotic expression plasmid containing HCV NS3 segment and protein expression in human HL-7702 hepatocytes.\n\nWorld J Gastroenterol 2006 Feb 21;12(7):1038-42\n\n3. RNA translocation and unwinding mechanism of HCV NS3 helicase and its coordination by ATP.\n\nNature 2006 Jan 5;439(7072):105-8\n\n4. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.\n\nBioorg Med Chem Lett 2006 Mar 15;16(6):1621-7\n\n5. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.\n\nCurr Med Chem 2005;12(20):2317-42\n\n6. Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease.\n\nBioorg Med Chem Lett 2005 Oct 15;15(20):4475-8